Valsartan Dosage Guidelines for Hypertension and Heart Failure

Dosing Recommendations

The American College of Cardiology recommends a target dose of 160 mg twice daily (320 mg total daily dose) for heart failure, with at least 50% of target dose (160 mg daily) recommended as the minimum effective dose 1, 2
For heart failure patients, therapies should be adjusted no more frequently than every 2 weeks to target doses or maximally tolerated doses, according to the American College of Cardiology 1
To achieve maximal benefits in heart failure with reduced ejection fraction (HFrEF), valsartan must be titrated to maximally tolerated doses, as recommended by the American College of Cardiology 1, 2

Higher doses of valsartan provide greater benefits than lower doses, with sustained AT1-receptor blockade over 24 hours achieved with the 160 mg dose, as demonstrated by the European Journal of Heart Failure 3
Many physicians use doses of valsartan for heart failure that are too low, which may not provide optimal benefits, according to the European Journal of Heart Failure 3, 4
Temporary dose reductions may be necessary for some patients, but efforts should be made to return to target doses when possible, as recommended by the European Journal of Heart Failure 4
Monitor for hypotension, renal impairment, and hyperkalemia, especially when initiating therapy or increasing doses, as advised by Circulation 5

The European Society of Cardiology recommends monitoring blood pressure, renal function, and electrolytes during dose titration, and checking renal function and potassium within 1-2 weeks after initiation or dose increases 6
The European Society of Cardiology advises against combining valsartan with ACE inhibitors, as this combination increases the risk of hyperkalemia and renal dysfunction, and also recommends avoiding the triple combination of ACE inhibitor + ARB + mineralocorticoid receptor antagonist 7
The European Society of Cardiology suggests avoiding NSAIDs unless essential, as they may attenuate diuretic effects and cause renal impairment 6, 7
The European Society of Cardiology recommends reconsidering the need for nitrates, calcium-channel blockers, and other vasodilators, and reducing or stopping them if possible, in patients with symptomatic hypotension 6

The European Society of Cardiology suggests that a specialist heart failure nurse may assist with education, follow-up, biochemical monitoring, and dose uptitration 6
The European Society of Cardiology recommends that patients with initial contraindications should be reevaluated to determine subsequent eligibility, and that underdosing is widespread in clinical practice, with less than 25% of patients ever titrated to target doses 6

The European Society of Cardiology recommends monitoring renal function and electrolytes 1-2 weeks after initiation and after each dose increase, with caution advised when creatinine >221 μmol/L (>2.5 mg/dL) or eGFR <30 mL/min/1.73 m² 8, 9
The European Society of Cardiology advises caution when systolic blood pressure <90 mmHg, and for symptomatic hypotension, reconsider need for nitrates, calcium-channel blockers, and other vasodilators; reduce or stop if possible 8
Significant hyperkalemia (K+ >5.0 mmol/L) requires caution and specialist advice, with monitoring of potassium within 1-2 weeks after initiation or dose increases, then every 3-6 months 8, 10
The European Society of Cardiology recommends avoiding potassium supplements, potassium-sparing diuretics, and "low-salt" substitutes with high potassium content, and avoiding NSAIDs unless essential, as they may attenuate diuretic effects and cause renal impairment 8, 9
The European Society of Cardiology advises against combining valsartan with ACE inhibitors, as this triple combination with mineralocorticoid receptor antagonists (MRAs) increases risk of hyperkalemia and renal dysfunction 9

The Val-HeFT trial demonstrated a 13.2% reduction in cardiovascular mortality and morbidity with valsartan at doses up to 320 mg/day, compared to placebo 11

The VALIANT trial demonstrated that valsartan 160 mg twice daily was noninferior to captopril for mortality outcomes, with a focus on post-myocardial infarction patients 12, 13
The Val-HeFT trial is mentioned in the context of heart failure, but its details are not provided due to the absence of a citation id, however, the VALIANT trial showed that combining valsartan with captopril had no increased benefit over captopril alone and had higher discontinuation rates due to adverse effects 12

An increase in creatinine up to 50% above baseline or to 3 mg/dL is acceptable, but if creatinine rises by 100% or exceeds 4 mg/dL, specialist advice should be sought, according to the European Journal of Heart Failure guidelines 14
Asymptomatic hypotension does not require treatment changes, as stated in the European Journal of Heart Failure 14

The American Heart Association, as published in Circulation, warns against combining valsartan with ACE inhibitors routinely, as this increases the risk of hyperkalemia and renal dysfunction without additional mortality benefit 15

In patients with severely reduced kidney function (creatinine clearance < 30 mL/min) or moderate hepatic impairment, the recommended starting dose of the sacubitril‑valsartan combination is 24 mg/26 mg taken twice daily. 16
For valsartan used alone in this population, clinicians should begin with a low dose and monitor renal function and electrolytes closely; while not an absolute contraindication, careful titration is advised. 16

In individuals aged ≥ 85 years or who are frail, dose increments should be spaced every 2–4 weeks rather than weekly to improve tolerability. 16
Blood pressure should be measured in both seated and standing positions at 1 minute and 3 minutes after standing to identify orthostatic hypotension. 16
Older adults often require lower maintenance doses of valsartan because they have a higher risk of symptomatic hypotension. 16